Results of randomized, Placebo (PL)-controlled Phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic Osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.

Congress : ASCO

Authors : Duffaud F, Blay JY, Mir O, Boudou-Rouquette P, Piperno-Neuman S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Thyss A, Isambert N, Delaye J, De Sousa Carvalho N, Schiffler C, Bouvier C, Vidal V, Chabaud S.

Experts group or program : Groupe Sarcome


Oral multikinase inhibitor REG has shown activity in GIST and non-adipocytic soft tissue sarcomas. We designed REGOBONE as a non-comparative phase II, double-blind, PL-controlled trial to study the efficacy and safety of REG for pts with metOS and other types of bone sarcomas. This trial consisted of 4 independent cohorts : metOS, Ewing sarcoma, chondrosarcoma, and chordoma. We report here the metOS cohort results.


En savoir plus